Katie Eder, Senior Editor

Pharmacists who participate in community-based diabetes care teams play a pivotal role in reducing A1C levels among patients with poorly controlled diabetes.

The results of an FDA safety review of omalizumab (Xolair) suggest the asthma drug slightly elevates the risk of serious cardiovascular and cerebrovascular adverse events.

Although mail-order pharmacies registered the most growth in overall pharmacy customer satisfaction from 2013, patients are still significantly more pleased with their interactions at brick-and-mortar pharmacies.

The FDA has cleared the Nova StatStrip Glucose Hospital Meter System to become the first blood glucose monitoring system for use in critically ill patients who have been hospitalized.

An experimental single-tablet regimen for treatment-naïve adults infected with HIV demonstrated non-inferiority to an FDA-approved combination pill in achieving undetectable viral load.

Although the initial uptake of the generic discount drug program (GDDP) was essentially nonexistent among vulnerable populations, patients' participation in the GDDP notably expanded as it matured.

Amgen has submitted a new drug application to the FDA for its novel leukemia candidate, blinatumomab.

Officials from the US Centers for Disease Control and Prevention are urging all Americans aged 6 months and older to receive flu shots for the impending influenza season.

A starter pack of Janssen Pharmaceuticals' rivaroxaban (Xarelto) will be available at pharmacies starting in October 2014.

On the heels of its recommendation to limit the use of testosterone replacement products, an FDA advisory panel voted to reject a novel oral testosterone candidate.

The FDA today approved dulaglutide (Trulicity), a once-weekly injectable therapy indicated to improve blood sugar control in adults with type 2 diabetes.

Just a dozen drug ingredients are the culprits behind nearly half of all emergency hospitalizations for unsupervised prescription drug ingestions among young children.

In a Phase 3 study, odanacatib significantly reduced the risk of osteoporotic fractures, but it also might have contributed to major cardiovascular events.

The FDA today approved AstraZeneca's naloxegol (Movantik) treatment for opioid-induced constipation in adults with chronic noncancer pain.

Extended-release naltrexone hydrochloride and bupropion hydrochloride (Contrave) has been approved as an adjunct therapy for chronic weight management in obese adults.

Pharmacies will soon be legally authorized to accept and safely dispose of patients' unused prescription medications.

The FDA has approved the use of Sanofi's Menactra vaccine as a booster immunization against meningococcal disease in patients at continued risk.

A New Jersey-based compounding pharmacy has voluntarily recalled 4 prescription preparations distributed in 4 states due to potential contamination.

Panelists discuss how community pharmacists are well-positioned for the new value-driven model of health care.

On the heels of what could arguably be the largest data breach identified to date, leading cyber security experts will help attendees of the 2014 NACDS Total Store Expo mitigate cyber attacks.

Drugs that contain hydrocodone will be moved to a more restrictive category of the Controlled Substances Act.

The FDA has expanded the use of the anticoagulant apixaban (Eliquis) to treat deep vein thrombosis and pulmonary embolism.

The FDA has approved the first needle-free device for injecting the Afluria influenza vaccine in adult patients aged 18 to 64 years.

The FDA has approved the first zinc transporter 8 autoantibody test that may help patients with type 1 diabetes mellitus receive more timely diagnosis and treatment for the disease.

The viral Ice Bucket Challenge and the first effort to estimate the prevalence of amyotrophic lateral sclerosis have raised awareness of the neurodegenerative disease.

Many patients with Parkinson's disease do not receive treatment for their depressive symptoms.

Mylan, Inc, has launched a therapeutically equivalent version of Precedex, while Hospira, Inc, has filed a lawsuit to challenge the generic approval.

The FDA has approved peginterferon beta-1a (Plegridy), a groundbreaking injectable therapy for patients with relapsing forms of multiple sclerosis.

A previous heart operation and recent struggles with the early stages of Parkinson's disease may have contributed to Robin Williams' suicide.